Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H32N2O |
Molecular Weight | 316.4809 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(COC1=CC=C(CN2CCCCC2)C=C1)CN3CCCCC3
InChI
InChIKey=PTKHFRNHJULJKT-UHFFFAOYSA-N
InChI=1S/C20H32N2O/c1-3-12-21(13-4-1)16-7-17-23-20-10-8-19(9-11-20)18-22-14-5-2-6-15-22/h8-11H,1-7,12-18H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15466448Curator's Comment: description was created based on several sources, including
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15466448
Curator's Comment: description was created based on several sources, including
JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at human (pKi=9.24) H3 receptor and was developed by Johnson & Johnson Pharmaceutical. During preclinical studies were shown that JNJ-5207852 might be useful in the treatment of cognitive impairment in epilepsy. On animal models was discovered, that this compound readily penetrates the brain tissue after subcutaneous administration.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15466448
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL264 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15466448 |
9.24 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15466448
in rats: On day 1 and following an overnight fast, animals were weighed (body weight range: 258–307 g) and each formulation was administered to a group of four male and four female rats. The i.v. formulation was administered by jugular venipuncture at a dose volume of 2 ml kg−1. The oral formulation was administered by gavage at a dose volume of 2 ml kg−1. Following dose administration, blood samples (0.25–0.40 ml) were collected from each animal by jugular venipuncture under isoflurane anesthesia. Blood samples were collected (using lithium heparin as the anticoagulant) at pre-dose and again at 0.08 (i.p. only), 0.25 (oral only), 0.33 (i.p. only), 0.5 (oral only), 1, 2, 4, 8, and 24 h post-dose.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15466448
Binding of 3H-JNJ-5207852 to rat H3 receptor were studied. Membranes from rat brain were incubated with increasing concentrations of 3H-JNJ-5207852 (0-70 nM)
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
JNJ-5207852
Created by
admin on Sat Dec 16 09:06:14 GMT 2023 , Edited by admin on Sat Dec 16 09:06:14 GMT 2023
|
PRIMARY | |||
|
DTXSID70377579
Created by
admin on Sat Dec 16 09:06:14 GMT 2023 , Edited by admin on Sat Dec 16 09:06:14 GMT 2023
|
PRIMARY | |||
|
2766326
Created by
admin on Sat Dec 16 09:06:14 GMT 2023 , Edited by admin on Sat Dec 16 09:06:14 GMT 2023
|
PRIMARY | |||
|
398473-34-2
Created by
admin on Sat Dec 16 09:06:14 GMT 2023 , Edited by admin on Sat Dec 16 09:06:14 GMT 2023
|
PRIMARY | |||
|
4I9OVB1G7D
Created by
admin on Sat Dec 16 09:06:14 GMT 2023 , Edited by admin on Sat Dec 16 09:06:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY